India aims for a $300 billion bioeconomy by 2030. What policy and financial interventions are needed to achieve this target?

India's bioeconomy has risen 16-fold from $10 billion (2014) to $165.7 billion (2024), contributing about 4.25% of GDP at a CAGR of 17.9% [1]. Sustaining that pace to $300 billion by 2030 requires interventions on two fronts — policy that shortens the lab-to-market journey, and finance that carries innovations past the scale-up stage.

Policy interventions needed

• Regulatory predictability: biotech products pass through multiple approval agencies; a single-window, time-bound clearance mechanism with clear biosafety and gene-editing norms would cut commercialization delays.
• Broadening the sectoral base: of India's 10,075+ biotech startups, roughly 70% are in medical/health biotech [2]; targeted policy support is needed for agri-, industrial, marine and bio-manufacturing segments.
• Deepening translational infrastructure: DBT-BIRAC's BioNEST bio-incubators — over 90 centres, largely healthcare-focused [3] — must extend into tier-2/3 cities and non-health domains.
• Research-industry linkage: stronger academia-industry IP sharing, contract-manufacturing capacity, and skilled bio-manufacturing talent, aligned with the Anusandhan National Research Foundation's mandate.

Financial interventions needed

• Scaling early-stage risk capital: the Biotechnology Ignition Grant (BIG) offers up to ₹50 lakh for 18 months and has backed nearly 1,000 innovators [4]; such grants seed ideas but cannot fund commercial scale-up.
• Bridging the "valley of death": Indian biotech startups have raised about $600 million in follow-on funding [2] — modest against a $300 billion goal. A dedicated fund-of-funds, growth-stage venture capital and credit-guarantee/risk-sharing support for capital-intensive bio-manufacturing plants is essential.
• Mobilising global capital: structured investor-startup platforms and IFSC-GIFT City routes can channel foreign investment directly into Indian biotech ventures.
• Demand-side finance: PLI-style production incentives and assured public procurement to de-risk first sales.

India's bioeconomy has grown on the strength of its science; the next phase depends on capital and regulatory certainty. A coordinated DBT-BIRAC-financial regulator framework that pairs incubation with scale-up funding can convert a large startup base into globally competitive enterprises, advancing both Atmanirbhar Bharat and SDG-9 on innovation-led industry.